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METHODS AND COMPOSITIONS FOR THE 
TREATMENT OF PSORIASIS 
REFERENCE TO RELATED APPLICATIONS 
This application claims the priority bene?t of US. Pro 
visional Patent Application No. 60/065,774, ?led Nov. 17, 
1997. The priority application is hereby incorporated herein 
by reference in its entirety. 
STATEMENT OF RIGHTS TO INVENTIONS 
MADE UNDER FEDERALLY SPONSORED 
RESEARCH 
This invention Was made in part during Work supported 
by a grant from the United States Public Health Service 
(CA72018). The government has certain rights in the inven 
tion. 
BACKGROUND 
Psoriasis is a chronic condition that affects as much as 
2.6% of the population of the developed World. A recent 
survey reported by the National Psoriasis Foundation esti 
mates that 6.4 million people suffers from psoriasis, of 
Which about 500,000 is rated as severe. The annual patient 
cost for treating psoriasis is currently estimated at $1.6 to 
$3.2 billion. Every year, about 400 people are granted 
disability by the Social Security Administration, and another 
400 people die from psoriasis-related causes. 
Characteristics of Psoriasis 
It is not knoWn What causes psoriasis, although there is 
evidence of a genetic predisposition and an autoimmune 
etiology. Onset may be triggered by systemic infections such 
as strep throat, skin injury, vaccinations, and certain oral 
medications such as steroids. Subsequently, the immune 
system is thought to induce in?ammation and excessive skin 
cell reproduction, Which can be exacerbated by additional 
factors such as stress and diet. 
In normal skin, the time for a cell to move from the basal 
layer through the granular layer is 4—5 Weeks. In psoriatic 
lesions, the time is decreased 7—10 fold because of a 
shortened cell cycle time, an increase in the absolute number 
of cells capable of proliferating, and an increased rate of 
division. T cell mediated immune responses appear to be 
responsible for the in?ammation and hyperproliferation of 
keratinocytes. Neutrophils are found in psoriatic lesions, 
associated With increased levels of plasminogen activator. 
Psoriatic ?broblasts have increased levels of enZymes 
involved in collagen synthesis, secondary to expansion of 
the papillary dermis. Psoriatic plaques comprise HLA-DR 
positive keratinocytes and Langerhans cells, and activated T 
cells expressing elevated levels of IL-2 receptors. 
The typical lesion of psoriasis is a Well-demarcated 
erythematous plaque, covered by thick, silvery scales. Pso 
riasis can become so extensive as to cause exfoliative 
erythroderma, in Which the entire epidermal surface is in a 
state of hyperproliferation. Gluttate psoriasis is a form of the 
disease folloWing streptococcal pharyngitis, With Widely 
distributed characteristic 1—3 cm lesions. Pustular psoriasis 
is characteriZed by numerous sterile pustules of 2—5 mm in 
diameter, and may lead to an acute, explosive, life 
threatening episode of fever, chills, leukocytosis, 
hypoalbuminemia, and hypocalcemia, demanding 
immediate, vigorous therapy. Previously stable plaque-type 
psoriasis can be acutely exacerbated by viral infections, 
particularly HIV. Psoriasis is also associated With ?ve dif 
ferent forms of psoriatic arthritis, including distal interpha 
rangeal involvement; an asymmetric, oligoarticular pattern; 
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a symmetric polyarthritis; arthritis mutilans; and sacroiliitis 
and spondylitis. 
The in?ammation and hyperproliferation of psoriatic tis 
sue is associated With a different histological and antigenic 
pro?le than normal skin. Dabelsteen et al. used a panel of 
anti-carbohydrate monoclonal antibodies to compare psori 
atic tissue With the surrounding dermis. The glycosylation 
pattern in psoriatic epithelium is changed in tWo Ways: some 
carbohydrates are expressed at an earlier stage of cell 
maturation. In addition, certain biosynthetic precursor anti 
gens not expressed in normal skin Were found in psoriatic 
skin. 
Paller et al. (1989) investigated the distribution of gan 
glioside GM3 using an antibody designated 8G9D8. At the 
electron microscope level, antibody deposition Was seen in 
the corneocyte envelope. Disposition Was signi?cantly 
decreased or absent in disorders of excessive keratinocyte 
proliferation, including squamous cell carcinomas, congeni 
tal ichthysiform erythrodermas, prokeratosis, and psoriasis. 
In a subsequent study, Paller et al. (1993) found that When 
GM3 Was added to keratinocytes from normal foreskin, 
lesional skin from patients With psoriasis or ichthyosis, and 
to cutaneous squamous carcinoma lines, it inhibited groWth 
in a dose-dependent manner at concentrations of 10—100 
pM. Con?uent undifferentiated keratinocytes Were least 
sensitive. The gangliosides GD3, 9-O-acetyl-GD2, and 
GD1b also inhibited keratinocyte proliferation. Ganglio 
sides GM1 and GD1a, and sialic acid had little effect. The 
authors concluded that preferential activation of sialyltrans 
ferase II may be involved in control of keratinocyte groWth, 
but not differentiation. 
Concharenko et al. studied ganglioside expression on the 
erythrocytes and serum of healthy subjects, and patients 
With psoriasis. During phases of exacerbation, a marked 
decrease Was observed in the content of GM2 and GM3 
fractions of the red cells, and GD1a decreased in serum. The 
presence of a neW monosialoganglioside fraction Was noted 
during exacerbation, both in serum and on red cells. The 
ganglioside spectrum of patients in clinical remission of 
psoriasis Was almost normal. 
Heidenheim et al. describe a monoclonal antibody desig 
nated UM4D4 Which recogniZes the cell surface marker 
CDW60. This marker is present on a subset of normal T cells, 
melanocytes, malignant melanoma cells, and hyperprolif 
erative psoriatic keratinocytes. CDW60 antibodies bind to 
the acetylated form of GD3. 74% of basal cell carcinomas 
express CDW60, Whereas CDW50 expression in normal skin 
is con?ned to melanocytes and a feW scattered keratinocytes 
at the basal cell layer. Skov et al. recently reported that in 
psoriatic skin, basal and suprabasal keratinocytes express 
CDW60. Cloned T cell lines obtained from lesional skin 
upon initiation Were found to release a cocktail of soluble 
factors including IL-4 and IL-13, that up-regulated CDW60 
expression on cultured normal keratinocytes. 
Currently Available Treatments for Psoriasis 
Classical treatments of psoriasis include calciptriene (a 
vitamin D3 derivative), topical coal tar preparations, sys 
temic antimitotic agents such as methotrexate, and retinoids, 
particularly etretinate. Extensive psoriasis can be treated by 
photosensitiZation With oral 8-methoxypsoralen, folloWed 
by ultraviolet A. Corticosteroids are given for psoriatic 
arthritis and acute attacks of pustular psoriasis. More 
recently, cyclosporin A has been tested in clinical trials at 
doses of 3—7 mg/kg With promising results, but associated 
With the risk of renal toxicity. There is no cure. 
Current biotechnology approaches to psoriasis treatment 
relate to a direct pharmaceutical-mediated attack, either on 
US 6,355,244 B1 
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cell proliferation or on the immune component of the 
disease. Japanese patent application JP 6145069 describes 
angiogenesis inhibitors comprising ganglioside GM3 or a 
GM3 analog as an active agent. At 100 pg/mL, GM3 shoWed 
groWth of normal human antioendothelial cells of 4.5><104 
on day 5, compared With 76><104 in controls. US. Pat. No. 
5,339,977 describes n-deacetyl-lysoganglioside derivatives 
for use as phospholipase A2 inhibitors for the treatment of 
proliferative and autoimmune diseases, including various 
forms of cancer, psoriasis, and rheumatoid arthritis. 
An IL-2 fusion toxin has been developed (Seragen, Inc.) 
that is designed to selectively destroy activated T cells in 
psoriatic plaques, leaving normal cells alone. The objective 
is to destroy activated T cells, and thereby clear the psoria 
sis. APhase II study has been performed in Which test doses 
of 5, 10, and 15 pig/kg Were administered per day. Compa 
rable improvement Was observed in patients With moderate 
to severe psoriasis. HoWever, in order to obtain this 
response, the compound Was administered three days per 
Week for four Weeks. 
Various formulations containing the compound BCX-34 
for psoriasis, cutaneous T cell lymphoma, and HIV infection 
have been tested (BioWorld Today, Sep. 29, 1997; see also 
WO 95/01355; WO 93/21187; WO 90/10631; US. Pat. Nos. 
5,008,270, 5,008,265, and 4,985,434). BCX-34 is a small 
molecule drug that inhibits purine nucleoside 
phosphorylase, a human enZyme believed to be involved in 
the proliferation of T cells. An oral formulation is being 
tested in an ongoing Phase I/II trial. A topical formulation 
advanced to the Phase III stage for both lymphoma and 
psoriasis. The Phase III psoriasis study shoWed only a 14% 
greater improvement in mean lesion scores in the treated 
group compared to placebos, Which for these studies Was not 
statistically signi?cant. 
Accordingly, there is a need for therapeutic compositions 
that are effective in managing psoriasis, particularly if they 
are effective When given on an occasional basis. The present 
invention relates to a strategy in Which the patient’s oWn 
immune system is recruited into an active role against the 
disease. 
SUMMARY OF THE INVENTION 
The invention provides methods of using compositions 
Which elicit an immune response against an antigen that is 
aberrantly expressed in psoriatic tissue. 
Accordingly, in one aspect, the invention provides meth 
ods for treating psoriasis in an individual, comprising 
administering a composition effective in stimulating a spe 
ci?c immunological response against an antigen aberrantly 
expressed in human psoriatic tissue. These composition(s) 
comprise an antigen that shares immunological characteris 
tics of an antigen that is aberrantly expressed in psoriatic 
tissue (such as human psoriatic tissue). Antigens aberrantly 
expressed in psoriasis include but are not limited to gan 
gliosides. While a detectable immunological response is 
likely to be bene?cial, efficacy can also be deduced by an 
improvement in symptoms or control of the psoriatic con 
dition beyond What Would be expected Without treatment. 
Certain embodiments of the invention include methods 
for treating psoriasis in an individual by eliciting an anti 
ganglioside immunological response in the subject. The 
immunological response can be elicited using any suitable 
immunogen and/or immunogenic composition, such as: (1) 
a ganglioside in an immunogenic form, such as GM2, GM3, 
GD1b, GD2, 9-O-acetyl GD2, GD3, GD3 lactone, 9-O 
acetyl GD3, and GT3; (2) an anti-idiotype for a ganglioside, 
such as the monoclonal antibodies 1A7, 4B5, or BEC-2; or 
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(3) a polynucleotide encoding an anti-idiotype for a gan 
glioside. The immunological response can have humoral or 
cellular components, and preferably has both. 
Further embodiments of the invention relate to preparing 
a composition for use in the treatment of psoriasis by 
preparing a composition comprising the determinant in an 
immunogenic form, or else raising an anti-idiotype against 
a monoclonal antibody that binds the antigenic determinant. 
Also embodied are methods for screening a composition for 
ef?cacy in treating psoriasis, involving administering the 
composition to human subjects, and monitoring disease 
progression (optionally in combination With immunological 
parameters) folloWing treatment. 
A further embodiment of the invention is a composition 
containing a ganglioside, an anti-idiotype for a ganglioside, 
or a polynucleotide encoding a ganglioside, packaged With 
an indication of its suitability for use in treating psoriasis. 
Further embodiments of the invention relate to the use of 
a component selected from the group consisting of a 
ganglioside, an anti-idiotype for a ganglioside, and an 
expression vector encoding an anti-idiotype for a 
ganglioside, in the manufacture of a medicament for the 
treatment of psoriasis. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a scheme for evaluating the effect of raising an 
anti-GD2 immunological response using an anti-idiotype 
vaccine to treat individuals With severe chronic plaque 
psoriasis. 
FIG. 2 is a depiction of the cDNA sequence (SEQ ID 
NO:1) and the amino acid sequence (SEQ ID NO:2) of the 
light chain variable region of 1A7 and adjoining residues. 
FIG. 3 is a depiction of the cDNA sequence (SEQ ID 
NO:3) and the amino acid sequence (SEQ ID NO:4) of the 
heavy chain variable region of 1A7 and adjoining residues. 
DETAILED DESCRIPTION 
It is an object of this invention to provide compositions 
that are neWly applied in the treatment of psoriasis in its 
various manifestations. Ideally, the compositions promote 
resolution of the clinical features, but stabiliZation of the 
condition is a satisfactory outcome. It is desirable that the 
effect be enduring, so that once an effect is achieved, 
readministration of the composition, if any, need occur on 
only an occasional basis. To accomplish this, the usual mode 
is to recruit active participation of the immune system of the 
host to react against a target antigen on psoriatic tissue. 
This invention is based in part on the discovery that 
patients immuniZed systemically With a suitable vaccine 
composition mount a response directed against a psoriasis 
speci?c antigen. As illustrated in Example 3, the response 
includes circulating antibodies that speci?cally adhere to 
affected tissue. Without intending to be bound by theory, it 
may be that the immune response to the target antigen 
promotes elimination or metabolic doWn-regulation of cells 
bearing the target antigen, or that it interferes mechanisti 
cally With a pathological phenotype of affected cells (such as 
proliferation) that is mediated, at least in part, by the target 
antigen. As a result, the presence of the immune response 
promotes the clinical resolution of the condition. 
Several target antigens are believed to be suitable as 
vaccine targets in psoriasis, and various types of vaccines 
can be used to obtain the desired result. Illustrative examples 
are given in the sections that folloW. 
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De?nitions 
In reference to the therapeutic methods and compositions 
of this invention, the term “psoriasis” refers to all skin 
conditions in the clinical arts described by this term, and to 
psoriatic-associated conditions, including psoriatic arthritis. 
“Psoriatic tissue” refers to tissue affected by psoriasis and 
affected cells contained Within the tissue, but not to cells that 
have migrated to the site such as leukocytes. Preferably, the 
psoriatic tissue is from a human. 
Particular molecules referred to in this disclosure, such as 
CEA, gangliosides designated GM1, GM2, and so on, are 
meant to include not only the intact molecule, but also 
allotypic and synthetic variants, synthetic analogs, fusion 
molecules, conjugates, and other derivatives that contain the 
parent molecule and its fragments that are recogniZed by 
antibodies speci?c for the intact molecule. 
An “effective amount” is an amount suf?cient to effect a 
bene?cial or desired clinical result. An effective amount can 
be administered in one or more doses. For purposes of this 
invention, an effective amount of ganglioside, antibody, or 
other composition is an amount that induces an immune 
response against a psoriasis antigen. 
“Immunological activity” of a particular immunogen or 
vaccine component refers to the ability to raise an immune 
response. A speci?c immune response may comprise 
antibody, B cells, T cells, and any combination thereof, and 
effector functions resulting therefrom. Included are the 
antibody-mediated functions ADCC and complement 
mediated cytolysis (CMC). A T cell response can include T 
helper cell function, cytotoxic T cell function, or 
in?ammation/inducer T cell function. A compound or com 
position able to elicit a speci?c immune response according 
to any of these criteria is referred to as “immunogenic”. 
An antigen that “shares immunological characteristics” 
With another antigen is an antigen that, When administered 
in appropriate form (such as, for example, alone, in con 
junction With an adjuvant, in association With (or conjugated 
to) a compound), elicits an immunological activity. For 
purposes of this invention, it is also understood that an 
antigen comprises an antigenic determinant(s) (as is Well 
understood in the art). 
A “polynucleotide” is a polymeric form of nucleotides of 
any length, Which contain deoxyribonucleotides, 
ribonucleotides, and nucleotide analogs in any combination. 
A“vector” refers to a recombinant DNA or RNA plasmid or 
virus that comprises a heterologous polynucleotide to be 
delivered into a target cell, either in vitro or in vivo. 
The terms “polypeptide”, “peptide” and “protein” are 
used interchangeably to refer to polymers of amino acids of 
any length, and may be interrupted by non-amino acids. 
An “aberrantly expressed antigen” is an antigen that is 
uniquely expressed, overexpressed, and/or underexpressed 
in conjunction With a disease state. For purposes of this 
invention, the disease state is psoriasis. 
An “immunogenic form” of an antigen is a form of or 
formulation comprising the antigen Which renders the anti 
gen immunogenic. Such forms include, but are not limited 
to, antigen alone, antigen in conjunction With one or more 
adjuvants, antigen in association With or conjugated to a 
moiety, such as a hapten. 
A “host cell” denotes a eukaryotic cell that has been 
genetically altered, or is capable of being genetically altered 
by administration of an exogenous polynucleotide, such as 
a recombinant plasmid or vector. When referring to geneti 
cally altered cells, the term refers both to the originally 
altered cell, and to its progeny. 
An “isolated” polynucleotide, polypeptide, ganglioside, 
or other component, is one that is substantially free of the 
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materials With Which it is associated in nature. Substantially 
free means at least 50%, preferably at least 75%, more 
preferably at least 90%, and even more preferably at least 
98% free of the materials With Which it is associated in 
nature, other than solvent. 
A “vaccine” is a pharmaceutical composition for human 
or animal use, Which is administered With the intention of 
conferring the recipient With a degree of speci?c immuno 
logical reactivity against a particular target, or group of 
targets. The immunological reactivity may be desired for 
experimental purposes, for treatment of a particular 
condition, for the elimination of a particular substance, or 
for prophylaxis. An active vaccine is a vaccine intended to 
elicit an immune response in the recipient that persists in the 
absence of the vaccine components. 
“Adjuvant” as used herein in the context of a pharma 
ceutical preparation is a chemical or biological agent given 
in combination With an antibody, polynucleotide or polypep 
tide to enhance its immunogenicity. 
An “individual” or “subject” treated according to this 
invention is a vertebrate, preferably a mammal, more pref 
erably a human. Mammals include, but are not limited to, 
farm animals, sport animals, rodents, primates, and pets. 
Other terms used in this disclosure are explained Where 
they arise. 
General Techniques 
The practice of the present invention Will employ, unless 
otherWise indicated, conventional techniques of molecular 
biology (including recombinant techniques), microbiology, 
cell biology, biochemistry and immunology, Which are 
Within the skill of the art. Such techniques are explained 
fully in the literature, such as, “Molecular Cloning: A 
Laboratory Manual”, second edition (Sambrook et al., 
1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); 
“Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods 
in EnZymology” (Academic Press, Inc.); “Handbook of 
Experimental Immunology” (D. M. Weir & C. C. BlackWell, 
eds.); “Gene Transfer Vectors for Mammalian Cells” (J. M. 
Miller & M. P. Calos, eds., 1987); “Current Protocols in 
Molecular Biology” M. Ausubel et al., eds., 1987); 
“PCR: The Polymerase Chain Reaction”, (Mullis et al., eds., 
1994); “Current Protocols in Immunology” (J. E. Coligan et 
al., eds., 1991). 
All patents, patent applications, articles and publications 
mentioned herein, both supra and infra, are hereby incorpo 
rated herein by reference. 
Target Antigens in Psoriatic Tissue 
The target antigen against Which a speci?c immune 
response is desired contains an epitope or antigenic deter 
minant Which is aberrantly expressed in psoriatic tissue. This 
means that it is present in cells of the affected tissue (or the 
surrounding milieu) in a manner that makes it accessible to 
the immune system at a level that is signi?cantly different 
than in cells of the same tissue type that are not affected. The 
cells in Which the epitope is aberrantly expressed Will be 
resident cells of the affected area, particularly keratinocytes 
or living epithelial cells, rather than migrant cells. For 
purposes of this invention, compositions described herein 
may comprise an antigen or an antigenic determinant. 
The aberrantly expressed antigenic determinant of interest 
can be of any chemical nature, including but not limited to 
protein epitopes, carbohydrate epitopes, and glycolipids 
such as gangliosides. Typically, the epitope is uniquely 
expressed and/or overexpressed in psoriatic tissue in a 
variety of different individuals, although variations in 
expression level may occur. Typically, the determinant Will 
be expressed at the cell surface or present as an insoluble but 
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accessible antigenic mass, rather than being a soluble factor. 
Histocompatibility Class I or Class II antigens are excluded 
by de?nition. 
Antigenic determinants that are aberrantly expressed can 
be identi?ed by a number of techniques known in the art. 
One method is to look for a particular messenger RNA 
transcript that is present in an unusual abundance in affected 
cells. Where the determinant is a protein antigen synthesiZed 
by the cell, a suitable proxy is, for example, mRNA encod 
ing the antigen. Where the determinant is a carbohydrate or 
glycolipid, a suitable proxy is, for example, mRNA encod 
ing an enZyme involved in forming a critical antigen-speci?c 
linkage in the synthetic pathWay. 
Methods for determining mRNA that is in an unusual 
abundance in one cell than another involves preparing 
mRNA from both cells, and then comparing the amount of 
each particular mRNA betWeen the preparations. A number 
of techniques for the comparison step are related in some 
Way to subtractive hybridiZation. One example involves 
producing positive and negative cDNA, respectively, from 
the ?rst and second RNA preparations, and looking for 
cDNA Which is not completely hybridiZed by the opposing 
preparation. Subtractive hybridiZation is described in the 
standard molecular biology reference books listed earlier. 
Another Way of comparing production of particular mes 
senger RNA is by differential display. This has been exten 
sively described by Liang et al. (1992, 1995), and has since 
been elaborated in a number of different Ways. In this 
technique, cDNA is prepared from only a subpopulation of 
each RNA preparation, and expanded via the polymerase 
chain reaction using primers of particular speci?city. Similar 
subpopulations are compared across several RNA prepara 
tions for expression differences by gel autoradiography. In 
order to survey the RNA preparations entirely, the assay can 
be repeated With a comprehensive set of PCR primers. The 
screening strategy more effectively includes multiple posi 
tive and negative control samples (Sunday et al.). By excis 
ing the corresponding region of the separating gel, it is 
possible to recover and sequence the cDNA. 
Antigenic determinants that are aberrantly expressed in 
psoriatic tissue can also be identi?ed directly using antibod 
ies directed against them. Psoriatic tissue or an antigen 
extract can be used to screen an immunoglobulin library. 
More conveniently, if the practitioner suspects a particular 
antigen of being aberrantly expressed in psoriatic tissue, an 
antibody speci?c to the antigen can be provided and used to 
test psoriatic tissue. Con?rmation of the overexpression can 
be obtained, for example, by performing a standard immu 
noassay on solubiliZed tissue extract of affected tissue, and 
comparing With a similar extract of unaffected tissue. More 
preferable are immunohistology techniques, using the anti 
body speci?c for the suspected target as the primary anti 
body. Asuitable aberrantly expressed determinant Will result 
in different staining in a section from affected tissue than 
unaffected tissue, and Will also shoW speci?city for particu 
lar cells in the affected sample. An illustration of this is 
provided in Example 1. 
Possible candidate antigens include any naturally occur 
ring ganglioside antigens, antigens that are aberrantly 
expressed in a spectrum of different cancers, such as CEA, 
alpha-fetoprotein and gp-72, and antigens that are aberrantly 
expressed in cancers of the skin, especially but not limited 
to melanoma. Melanoma-associated antigens include the 
gangliosides GM2, GD2, GD3, and their derivatives and 
analogs; HMW-MAA, MPG, and gp-75. Also of interest are 
the Thomsen-Friedenreich (T) antigen (Gal[31-3GalNAcot 
O-Ser), Tn, and sialylated Tn (NeW5Acot2-6GalNAcot-O 
Ser). Also of interest is the cell surface marker CDW60. 
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Glycolipids suitable as target antigens include any of the 
monosialyl, disialyl and trisialyl gangliosides that occur 
naturally on cells in psoriatic tissue. Preferred target anti 
gens are GM1, GD1a, GT1, GT2, and especially GM2, 
GM3, N-glycolyl GM3, GD1b, 9-O-acetyl GD2, GD3, GD3 
lactone, 9-O-acetyl GD3, and GT3. 
Types of Therapeutic Compositions used in this Invention 
Once a suitable target antigen is identi?ed, a composition 
is designed With a vieW to recruiting a speci?c immune 
response in the subject to be treated against the aberrantly 
expressed determinant. Any type of composition capable of 
eliciting the desired speci?c immune response is suitable. 
In some embodiments, the invention employs a compo 
sition comprising the target antigen, or a modi?ed version, 
in an immunogenic form. In other embodiments, an effective 
amount of a composition is employed, Wherein an effective 
amount is an amount suf?cient to elicit the desired immune 
response. Accordingly, the antigen is administered in a 
composition such that an immune response is elicited. For 
example, the target antigen can be provided by obtaining an 
enriched fraction from a suitable tissue source or cell line, 
such as keratinocytes, using one of the assays described 
earlier to folloW the desired activity. An illustration of this 
is a vaccine for the Tn and sialylated Tn antigens, Which can 
be prepared from ovine submaxillary gland mucin (O’Boyle 
et al.). 
More typically, the target antigen is provided in synthetic 
form. Where the target antigen is not previously knoWn, it is 
?rst characteriZed by isolation of the antigen complex, or an 
mRNA encoding it. Protein antigens can then be prepared by 
standard peptide synthesis, or by expressing a polynucle 
otide encoding it in a suitable host cell. Carbohydrate and 
other non-protein antigens are generally prepared by chemi 
cal synthesis, or by a combination of synthetic and isolation 
techniques. For example, use of cancer antigens as vaccine 
preparations is described in BE 1008391 and W0 92/ 19266 
(CEA antigen), and in US. Pat. No. 5,141,742 (melanoma 
associated antigen p97). 
Also suitable for use in immunogenic compositions to 
raise an anti-ganglioside response are any monosialyl, disia 
lyl and trisialyl gangliosides, along With synthetic 
derivatives, including 9-O-acetyl derivatives, lactone and 
lactam derivatives and analogs, and episialo derivatives; 
many of Which are referred to elseWhere in this disclosure. 
Included in the practice of the invention is the application 
to psoriasis of ganglioside vaccines and other formulations 
originally designed for cancer treatment or other modes of 
clinical care. For example, Helling et al. and Livingston et 
al. describe ganglioside GD3, in the form of synthetic 
multiple antigenic peptides, as conjugates With albumin, 
KLH, or membrane proteins of Neiseeria meningitidis, or as 
proteosomes. A vaccine for stimulating or enhancing pro 
duction of antibodies against 9-O-acetyl GD3 is outlined in 
US. Pat. No. 5,102,663. European patent application EP 
0443518 outlines a cancer vaccine containing episialo com 
plex carbohydrates, particularly epiGM3, epiGM4, or 
epiGM5. European patent application EP 0661061 outlines 
vaccine compositions for eliciting an immune response 
against N-glycosylated gangliosides for cancer treatment, 
particularly N-glycolyl GM3. PCT patent application WO 
93/10134 outlines ganglioside lactam analogue derivatives 
that are proposed for use in a vaccine for cancer treatment. 
Cheresh et al. describe the biosynthesis and expression of 
the disialoganglioside GD2, a relevant target antigen on 
small cell lung carcinoma for monoclonal antibody 
mediated cytolysis. PCT patent application WO 94/16731 
outlines ganglioside-KLH conjugate vaccines With the adju 
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vant QS-21, using a ganglioside selected from GM2, GM3, 
GD2, GD3, GD3 lactone, O-acetyl GD3, and GT3. The 
metabolism of these gangliosides is altered in cancers of 
neuroectodermal origin, including melanoma (Hamilton et 
al.). Progenics Pharmaceuticals Inc. is testing a GM2-KLH 
conjugate With the adjuvant QS-21 in a Phase III clinical 
trial of patients With melanoma under the product name 
GMK. Also being tested is a second ganglioside conjugate 
vaccine, MGV, comprising a combination of KLH 
conjugated GD2 and GM2. The vaccine is proposed for 
therapy not only of melanoma, but also of colorectal cancer, 
lymphoma, small cell lung cancer, sarcoma, gastric cancer, 
and neuroblastoma (Progenics Prospectus). Any of these 
compositions or their active components may be adapted for 
psoriasis treatment in accordance With this invention. 
Another illustration of a composition suitable for eliciting 
a speci?c immunological response against a target antigen in 
psoriasis is an anti-idiotype moiety. This approach to immu 
niZation arises from the netWork theory of Jerne, involving 
a second antibody (Ab2) raised against a ?rst antibody 
(Ab1) Which in turn is speci?c for the target. The Ab2 is 
selected not only for its ability to bind Ab1 speci?cally, but 
also for its ability to stimulate a further antibody (Ab3) that 
cross-reacts With the target. The use of anti-idiotypes in 
cancer treatment is described generally in US. Pat. No. 
5,053,224. 
The term “anti-idiotype” or “anti-idiotype moiety” as 
used throughout this application is de?ned to include not 
only intact antibody molecules, but any molecules compris 
ing at least one variable region or portion of a variable 
region With the desired functional properties. The variable 
region Will typically comprise a VH—VL pair, but may 
alternatively be made up of other combinations of variable 
chains from antibodies or T cell receptors. Variable region 
fragments, fusion molecules, chimeras, and humaniZed vari 
ants are included, so long as the requisite functional prop 
erties are retained. The variable region may be presented in 
any suitable form, including but not limited to intact anti 
body molecules, antibody fragments (such as Fab, F(ab‘)2, 
and Fv), multiple antigen proteins, and various antigen 
binding constructs. Examples of constructs of particular 
interest include fusion constructs, such as single chain 
variable region polypeptides (scFv), in Which a single 
VH—VL pair are linked through a ?exible peptide linker 
sequence in a manner that permits the polypeptide to fold 
into the three-dimensional conformation of a single variable 
region. Also included are diabodies, in Which tWo variable 
regions are linked by a shorter linker that prevents folding 
into a single variable region, but permits chains to dimeriZe 
into bivalent molecules With tWo VH—VL sites. Other con 
structs of interest include polymeric forms, Which contain a 
plurality (i.e., more than one) polypeptide. Polymeric forms 
may be linear or branched. 
The desirable characteristics of an anti-idiotype moiety 
are an ability to bind an antibody speci?c for the target 
antigen (Ab1), and the ability to elicit an antibody speci?c 
for the target antigen When injected into the intended sub 
ject. As used herein, reference to an anti-idiotype for a 
particular antigen (for example, an anti-idiotype for a 
ganglioside) means an anti-idiotype that elicits an active 
immune response speci?c for the particular antigen in an 
individual When administered in an immunogenic form. 
To obtain an anti-idiotype With the features desired, a 
screening process is employed. A preferred screening 
method involves the folloWing steps: (1) Positive selection 
for antibody (or at least a molecule having a variable region) 
capable of binding to the Ab1; (2) Negative selection against 
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antibody recogniZing isotypic or allotypic determinants of 
the Ab1; (3) Positive selection for an ability to inhibit the 
binding of Ab1 to the target antigen; and (4) Positive 
selection for an ability to induce a humoral immune 
response against the target antigen in experimental animals. 
Typically, the ?rst step involves multiple immuniZation of an 
animal With the Ab1, preparation and cloning of hybridoma 
cells from the immune animal, and then testing of the cells 
for the desired speci?city on a clone-by-clone basis. 
HoWever, other Ways of raising or selecting antibody or 
antibody equivalents are also suitable. Immunocompetent 
phage can be constructed to express immunoglobulin vari 
able region segments on their surface. See Marks et al., NeW 
Engl. J. Med. 335:730, 1996; International patent applica 
tions WO 94/13804, WO 92/01047, and WO 90/02809; and 
McGuinness et al., Nature Biotechnol. 14:1149, 1996. Phage 
of the desired speci?city can be selected, for example, by 
adherence to Ab1 attached to a solid phase, and then 
ampli?ed in E. coli. A further elaboration of the screening 
method and its use in preparing an anti-idiotype for a 
ganglioside is provided in International Patent Application 
WO 96/22373. 
Of particular interest are the monoclonal antibodies (and 
derivatives With the same immunogenic properties) With the 
designations 1A7, 4B5, and BEC-2. The 1A7 antibody is an 
anti-idiotype for ganglioside GD2, and is described in US. 
Pat. No. 5,612,030 and International Patent Application WO 
96/22373. It Was deposited With the American Type Culture 
Collection (ATCC), noW located at 10801 University Blvd., 
Manassas Va. 20110-2209, USA, on Dec. 28, 1994 under 
Accession No. HB-11786. The 4B5 antibody is an anti 
idiotype for ganglioside GD2, and is described in US. Pat. 
No. 5,653,977. The BEC-2 antibody is an anti-idiotype for 
ganglioside GD3, and is described in US. Pat. No. 5,529, 
922. Also of interest are the anti-GD2 anti-idiotypes of 
Cheung et al., and the anti-GM3 anti-idiotypes of Yamamoto 
et al., one of Which Was recombined by Hastings et al. as a 
chimera With human ogle K constant region sequences. 
Preferably, anti-idiotype antibody 1A7 (for a functional 
portion thereof, as described beloW) is used. 1A7 Was raised 
against the anti-GD2 monoclonal antibody designated 
14G2a. 
The 1A7 antibody can be prepared in several Ways. It is 
most conveniently obtained from the hybridoma deposited 
With the ATCC under Accession No. HB-11786, or the 
progeny thereof. For example, the cells can be cultured in a 
suitable medium, and spent medium can be used as an 
antibody source. Optionally, matrix-coated channels or 
beads and cell co-cultures may be included to enhance 
groWth of antibody-producing cells. For the production of 
large amounts of antibody, it is generally more convenient to 
obtain an ascites ?uid. The method of raising ascites gen 
erally comprises injecting hybridoma cells into an immu 
nologically naive histocompatible or immunotolerant 
mammal, especially a mouse. The mammal is optionally 
primed for ascites production by prior administration of a 
suitable composition; for example, Pristane. 
Alternatively, 1A7 can be chemically synthesiZed in con 
junction With standard methods of protein synthesis. A 
suitable method is the solid-phase Merri?eld technique. 
Automated peptide synthesiZers are commercially available, 
such as those manufactured by Applied Biosystems, Inc. 
(Foster City, Calif.). 
1A7 may also be obtained by employing routine recom 
binant methods such as described in Sambrook et al. (1989). 
For instance, using the sequences and information provided 
herein, a polynucleotide encoding either the 1A7 heavy or 
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light chain can be cloned into a suitable expression vector 
(Which contains control sequences for transcription, such as 
a promoter). The expression vector is in turn introduced into 
a host cell. The host cell is groWn under suitable conditions 
such that the polynucleotide is transcribed and translated 
into a protein. Heavy and light chains of 1A7 may be 
produced separately, and then combined by disul?de bond 
rearrangement. Alternatively, vectors With separate poly 
nucleotides encoding each chain of 1A7, or a vector With a 
single polynucleotide encoding both chains as separate 
transcripts, may be transfected into a single host cell Which 
may then produce and assemble the entire molecule. 
Preferably, the host cell is a higher eukaryotic cell that can 
provide the normal carbohydrate complement of the mol 
ecule. The 1A7 thus produced in the host cell can be puri?ed 
using standard techniques in the art. A polynucleotide 
encoding 1A7 for use in the production of 1A7 by any of 
these methods can in turn be obtained from the hybridoma 
producing 1A7, or be produced synthetically or recombi 
nantly from the DNA sequence provided herein. 
Methods of antibody isolation are Well knoWn in the art. 
See, for example, HarloW and Lane (1988) Antibodies: A 
Laboratory Manual, Cold Spring Harbor Laboratory, NeW 
York. The 1A7 antibody is a mouse immunoglobulin of the 
IgG1 subclass, and may be isolated by any technique suit 
able for immunoglobulins of this isotype. Puri?cation meth 
ods may include salt precipitation (for example, With ammo 
nium sulfate), ion exchange chromatography (for example, 
on a cationic or anionic exchange column run at neutral pH 
and eluted With step gradients of increasing ionic strength), 
gel ?ltration chromatography (including gel ?ltration 
HPLC), and chromatography on affinity resins such as 
protein A, protein G, hydroxyapatite, and anti 
immunoglobulin. 1A7 may also be puri?ed on affinity 
columns comprising the 14G2a paratope; for example, in the 
form of a puri?ed Ab1 or Ab3. Preferably, 1A7 is puri?ed 
from BALB/c ascites using Protein-A-CL-SEPHAROSETM 
4B chromatography folloWed by chromatography on a 
DEAE-SEPHAROSETM 4B ion exchange column. 
Alternatively, an active portion (see above under descrip 
tion of “anti-idiotype” or “anti-idiotype moiety”) of 1A7 
may be used, Which comprise a portion of or an entire 
variable region of 1A7. Examples of variable region 
(Whether intact or fragments) constructs have been provided 
above. FIGS. 2 and 3 provide the polypeptide sequences of 
the light and heavy chain variable regions as Well as the 
polynucleotide sequences encoding the variable regions. 
Preparation of these 1A7 polypeptides employs standard 
techniques, such as recombinant techniques, in the art. 
1A7 polypeptides can be produced by proteolytic or other 
degradation of 1A7, by recombinant methods (i.e., single or 
fusion polypeptides) as described above or by chemical 
synthesis. 1A7 polypeptides, especially shorter polypeptides 
up to about 50 amino acids, are conveniently made by 
chemical synthesis. Methods of chemical synthesis are 
knoWn in the art and are commercially available. For 
example, a 1A7 polypeptide could be produced by an 
automated polypeptide synthesiZer employing the solid 
phase method. 
Preferably, the polypeptides are at least partially puri?ed 
from other cellular constituents. Preferably, the polypeptides 
are at least 50% pure. In this context, purity is calculated as 
a Weight percent of the total protein content of the prepa 
ration. More preferably, the proteins are 50—75% pure. More 
highly puri?ed polypeptides may also be obtained and are 
encompassed by the present invention. For clinical use, the 
polypeptides are preferably highly puri?ed, at least about 
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80% pure, and free of pyrogens and other contaminants. 
Methods of protein puri?cation are knoWn in the art and are 
not described in detail herein. Alternatively, if a 1A7 
polypeptide(s) is expressed in a suitable storage medium, 
such as a plant seed, the 1A7 polypeptide need not be 
puri?ed and could even be administered Without puri?ca 
tion. Fiedler et al. (1995) Biotechnology 13:1090—1093. 
1A7 polypeptides can be obtained from intact 1A7, Which 
can in turn be isolated from the hybridomaATCC Accession 
No. HB-11786 producing 1A7, Which is described in 
co-oWned U.S. Pat. No. 5,612,030 and International Patent 
Application WO 96/22373. Techniques of isolating antibod 
ies from hybridomas are Well knoWn in the art. See, e.g., 
HarloW and Lane (1988). Once intact 1A7 is obtained, 1A7 
polypeptides can be obtained by degradation of intact 1A7, 
by using, for example, proteolytic enZymes (proteinases). 
Examples of proteolytic enZymes include, but are not lim 
ited to, trypsin, plasmin, and thrombin. Intact 1A7 can be 
incubated With one or more proteinases, or the digestions 
can be performed sequentially. The nature and extent of the 
proteolytic cleavage Will depend upon the desired polypep 
tide length as Well as the enZymes used. These techniques 
are Well knoWn in the art. Alternatively, or in addition, intact 
1A7 can be treated With disul?de reducing agents to disas 
sociate the molecule. 
1A7 polypeptides can also be made by chemical synthesis 
using techniques knoWn in the art. 1A7 polypeptides can 
also be made by expression systems, using recombinant 
methods. The availability of 1A7 polynucleotides encoding 
1A7 polypeptides permits the construction of expression 
vectors encoding intact 1A7, functionally equivalent frag 
ments thereof, or recombinant forms of 1A7. A polynucle 
otide encoding the desired 1A7 polypeptide, Whether in 
fused or mature form, and Whether or not containing a signal 
sequence to permit secretion, may be ligated into expression 
vectors suitable for any convenient host. Both eukaryotic 
and prokaryotic host systems can be used. The polypeptide 
is then isolated from lysed cells or from the culture medium 
and puri?ed to the extent needed for its intended use. 
Puri?cation or isolation of the polypeptides expressed in 
host systems can be accomplished by any method knoWn in 
the art. For example, cDNA encoding intact 1A7 or a 
fragment thereof can be operatively linked to a suitable 
promoter, inserted into an expression vector, and transfected 
into a suitable host cell. The host cell is then cultured under 
conditions that alloW transcription and translation to occur, 
and the desired polypeptide is recovered. Other controlling 
transcription or translation segments, such as signal 
sequences that direct the polypeptide to a speci?c cell 
compartment (i.e., for secretion), can also be used. Examples 
of prokaryotic host cells are knoWn in the art and include, for 
example, E. coli. Examples of eukaryotic host cells are 
knoWn in the art and include yeast, avian, insect, plant, and 
animal cells such as COS7, HeLa, CH0 and other mamma 
lian cells. 
For scFv fragments, light and/or heavy chain variable 
regions are linked using a short linking peptide. Bird et al. 
(1998) Science 242:423—426. An example of a linking 
peptide is (GGGGS)3(SEQ ID N015), Which bridges 
approximately 3.5 nm betWeen the carboxy terminus of one 
variable region and the amino terminus of the other variable 
region. Linkers of other sequences have been designed and 
used. Bird et al. (1988). Usually the linkers are selected to 
have little to no immunogenicity. For asymmetrical linkers, 
the scFvs can be assembled in any order. Generally, the 
entire variable regions are included in the scFv, Which may 
be produced either recombinantly or synthetically. 
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Another illustration of a composition suitable for eliciting 
a speci?c immunological response against a target antigen in 
psoriasis is an expression vector encoding a polypeptide 
Which is used in an immunogenic composition. The 
polypeptide encoded by the vector is either one comprising 
the antigenic determinant that is aberrantly expressed in 
psoriatic tissue, or else an anti-idiotype for the aberrantly 
expressed determinant. The encoding region is linked in the 
vector to suitable transcription and translation control ele 
ments that permit the encoding region to be expressed in the 
intended subject upon administration. 
Vaccines made up of naked polynucleotides are generally 
described in Tang et al. (1992) Nature 356: 152—154. Viral 
vectors are also suitable, including by Way of example, 
vectors based on herpes viruses, hepadna viruses, Sindbis 
virus, pseudotype retroviral vectors, adenovirus, adeno 
associated virus. Where the encoding region encodes an 
anti-idiotype, of particular interest are vectors based on 
vaccinia virus that can be used in vaccine preparations 
(Moss (1991) Science 252: 1662—1667). Such vectors can be 
constructed, for example, by homologous recombination of 
vaccinia plasmids and Wild-type WR strain of vaccinia virus 
using CV-1 cells, according to the procedure of Mackett et 
al. (DNA Cloning, Vol. II, D. M. Glover, ed., IRL Press 
1985). 
Formulation of Therapeutic Compositions 
The preparation of pharmaceutical compositions is con 
ducted in accordance With generally accepted procedures for 
the preparation of pharmaceutical preparations. See, for 
example, Remington’s Pharmaceutical Sciences 18th Ea'i 
tion (1990), E. W. Martin ed., Mack Publishing Co., Pa. 
Depending on the intended use and mode of administration, 
processing optionally includes sterilizing, mixing With 
appropriate non-toxic and non-interfering components, 
dividing into dose units, or enclosing in a delivery device. 
Protein vaccines used in this invention typically comprise 
an adjuvant, Which may be the same as or in addition to the 
excipient or carrier. Examples of adjuvants include but are 
not limited to aluminum hydroxide, alum, QS-21 (US. Pat. 
No. 5,057,540), DHEA (US. Pat. Nos. 5,407,684 and 5,077, 
284) including its precursors and modi?ed forms (e.g., 
DHEA-S, the sulfonated form of DHEA), [32 microglobulin 
(WO 91/16924), muramyl dipeptides, muramyl tripeptides 
(US. Pat. No. 5,171,568), monophosphoryl lipid A (US. 
Pat. No. 4,436,728; WO 92/16231) and its derivatives, such 
as various forms and generations of DETOXTM and BCG 
(US. Pat. No. 4,726,947). Other suitable adjuvants are 
aluminum salts, squalene mixtures (SAP-1), muramyl 
peptide, saponin derivatives, mycobacterium Wall 
preparations, mycolic acid derivatives, nonionic block 
copolymer surfactants, Quil A, cholera toxin B subunit, 
polyphosphaZene and derivatives, and immunostimulating 
complexes (ISCOMs) such as those described by Takahashi 
et al. (1990) Nature 344:873—875. For veterinary use and for 
production of antibodies in animals, complete and incom 
plete Freund’s adjuvant can be used. A preferred vaccine 
composition for peptides and anti-idiotypes or peptide 
derivatives thereof is prepared by mixing With aluminum 
hydroxide and incubated to about 48° C. for about 30 min. 
Especially preferred adjuvants include QS-21 and 
RIBITMPC. The QS-21 molecule consists of a triterpene 
glycoside With the general structure of a quillaic acid 
3,28-O-bis glycoside. There are tWo structural isomers des 
ignated V-1 and 2-1 at a typical ratio of ~2:1, both of Which 
have adjuvant activity. QS-21 has been shoWn to stimulate 
a response against T-dependent antigens and unconjugated 
T-independent antigens. QS-21 also augments the induction 
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of MHC Class I cytotoxic T lymphocytes to subunit antigen 
vaccines, as Well as antigen-speci?c cellular proliferation. 
Preclinical trials con?rm its safety and ef?cacy at 100 
pig/dose. QS-21 is supplied by Aquila Biopharmaceutical, 
Inc. in Worchester, Mass. 
The composition can optionally also contain other active 
medicinal agents, and/or non-active ingredients such 
carriers, and auxiliary substances such as Wetting or emul 
si?ng agents, and pH buffering agents. Additives of particu 
lar interest are adjuncts that enhance the immunogenic 
effect, such as mitogens or stimulatory cytokines. Of par 
ticular interest as adjunctive agents for anti-idiotype com 
positions are interleukins, particularly IL-2. The composi 
tion is typically formulated in liquid form, but can also be 
freeZe-dried for reconstitution by hydration. 
The route of administration is selected according to the 
formulation of composition and the intended effect. In the 
more usual embodiments of this invention, the composition 
is formulated and administered so as to stimulate a systemic 
response in the subject. With this in vieW, possible routes of 
administration include intracutaneous, subcutaneous, 
intramuscular, intraperitoneal, intradermal, oral, intranasal, 
intradermal, and intrapulmonary (i.e., by aerosol). Protein 
vaccines of this invention for human use are typically 
administered by a parenteral route, most preferably subcu 
taneous. Aseries of injections is preferably given at different 
subcutaneous sites. 
In other embodiments, the composition is formulated and 
administered to produce a local effect (i.e., is formulated for 
topical administration). These compositions are generally 
used to boost at an affected site a response in an individual 
Where a systemic immunological response against the target 
antigen has already successfully been induced, although 
pre-generation of a systemic immune response is not 
required. In these embodiments, the composition is gener 
ally in the form of a cream or gel, or other combination of 
the active ingredient and a readily absorbable or evaporable 
excipient. The composition is then administered on the skin 
at the affected site. Accordingly, the invention provides 
topical formulations of any of the target antigen (antigenic 
determinants) described herein, such as gangliosides, anti 
idiotype moieties (i.e., anti-idiotype moieties, including 
anti-idioptype antibodies, for any of the gangliosides 
described herein), and the expression vectors described 
herein. Preferably, a topical formulation comprises 1A7. 
Examples of suitable topical formulations, Which are Well 
knoWn in the art, include ointments, creams, and gels. 
In certain embodiments of the invention, the composition 
is specially designed for psoriasis, comprising a formulation 
and dose that is designed especially to maximiZe manage 
ment of the psoriatic condition. In other embodiments, the 
composition is formulated in a similar fashion as it Would be 
for use in another type of therapy, such as for cancer 
treatment, that shares a common objective, such as the 
eliciting of an immunological response against an antigen 
that is aberrantly expressed in either condition. 
Preferably, compositions useful for treating psoriasis 
according to the present invention are accompanied by 
Written instructions as part of the packaging or in a product 
insert. The Written instructions can simply indicate that 
psoriasis (in any one of its many forms) is a suitable 
indication for the use of the composition. Optimally, the 
instructions Will also indicate suitable subjects and 
conditions, the recommended route of administration, 
timing, and dosage, contraindications, potential side effects, 
and expected bene?t. 
The invention accordingly provides a composition for use 
(or use of any of the compositions described herein) in the 
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preparation of a medicament for use in the treatment of 
psoriasis. These compositions comprise any of the embodi 
ments described herein. In one embodiment, the invention 
provides use of a component selected from the group 
consisting of i) a ganglioside; ii) an anti-idiotype moiety for 
a ganglioside; and iii) an expression vector encoding an 
anti-idiotype for a ganglioside in the manufacture of a 
medicament for the treatment of psoriasis. The psoriasis to 
be treated may be any of gluttate psoriasis, pustular 
psoriasis, plaque-type psoriasis, psoriatic arthritis, and/or 
chronic plaque psoriasis. The ganglioside may be any of 
GM2, GM3, GD1B, GD2, 9-O-acetyl GD2, GD3, GD3 
lactone, 9-O-acetyle GD3, and GT3. The anti-idiotype moi 
ety may be any of 1A7, 4B5, or BEC-Z, and is preferably 
1A7. 
Use of Therapeutic Compositions 
Patients suitable for treatment according to this invention 
have clinical or histological features of psoriasis, particu 
larly gluttate psoriasis, pustular psoriasis, plaque-type 
psoriasis, or psoriatic arthritis. The compositions can also be 
given to patients Who have no outWard signs of psoriasis, but 
are at risk for developing the disease especially in its more 
severe manifestations (because of a genetic predisposition, 
family history or previous manifestations), although this is 
less typical. Since the effectiveness of this invention is 
believed to involve a host immunological response against 
the target antigen, the therapeutic compositions are pre 
dicted to be more effective When the individual is not 
immunode?cient or immunocompromised due to a genetic 
abnormality, infection, or by chemical treatment. 
The amount of the immunogenic substance administered 
at one time is selected With a vieW to clinical safety, and to 
achieve the initial desired immunological and clinical result 
Within a feW administrations. The range of effective con 
centrations for protein immunogens is generally about 10 pg 
to 20 mg, and typically 200 pg to 10 mg, With the tendency 
toWards higher values Where the immunogenic determinant 
is a proportionately smaller part of the protein. The range of 
effective concentrations for polynucleotide vaccines is gen 
erally about 10 pg to 500 pg of nucleic acid, typically about 
50 to 100 pg. Since clinical ef?cacy is believed to correlate 
With the extent of the speci?c immunological response 
obtained, a dose that is clinically effective can in principle 
be predicted by determining an immunogenic dose in an 
animal model, and then scaling the dose appropriately for 
human use. Administrations are typically conducted on a 
Weekly or biWeekly basis until there is evidence of an 
immunological or clinical response. Administration can then 
be continued on a less frequent basis, such as biWeekly, 
monthly, or bimonthly as appropriate. 
Treatment according to this description can optionally be 
combined With other regimens focused on clinical 
symptoms, including but not limited to local treatment With 
topical steroids, topical calcipotriol, or ultraviolet light; or 
systemic treatment With methotrexate, etretinate or 
cyclosporine. Parallel treatment can also be conducted With 
a vieW to activating the immune system to make it more 
responsive to the vaccine, such as simultaneous administra 
tion of a mitogen or cytokine. In one example, IL-2 is 
injected at a collateral site at a dose of about 1.5 to 15><106 
U m-2 day_1, either throughout the priming phase of vaccine 
treatment, or as a pulse given a feW consecutive days on a 
biWeekly schedule, or any reasonable variation. 
Clinical response is measured around about the time of 
administration and on regular folloW-up. Immunological 
response can also be measured, if desired, by collecting 
periodic blood samples for analysis. 
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Presence of antibody activity (for example, against a 
particular ganglioside or a particular anti-idiotype) can be 
determined by standard immunoassay of serum or plasma 
samples from the treated subject. For anti-idiotype activity, 
the sample is preincubated With autologous immunoglobulin 
or adsorbed on a suitable af?nity resin to remove antibody 
activity against isotypic and allotypic determinants. In one 
assay method, the sample is incubated in a microtiter plate 
Well previously coated With the target antigen; the Well is 
Washed, and then the reaction is developed With an isoto 
pically or enZymatically labeled anti-immunoglobulin 
reagent. Results are compared With those using preimmune 
serum or serum from subjects immuniZed With an unrelated 
antigen. Speci?city can also be measured by Western blot. 
The antigen is separated by electrophoresis over a polyacry 
lamide gel, blotted onto nitrocellulose, and then developed 
With the sample. In an third example, the sample is incubated 
With cells that do or do not express the antigen of interest, 
and then developed using a ?uorescently tagged anti 
immunoglobulin. Staining frequency and intensity can then 
be measured by FACS analysis. A model cell line is one 
expressing GD2 is M21/P6. In a fourth example, the sample 
is overlaid onto a histological sample from a psoriatic lesion, 
as may be taken from the treated subject, and then developed 
With an enZyme-labeled anti- immunoglobulin. This is illus 
trated in Example 3. The nature of the response in the sample 
can be further characteriZed in any of these assays by 
competition With an antibody With knoWn activity for the 
target antigen. A model antibody for GD2 is monoclonal 
antibody 14G2a. 
Complement mediated cytotoxicity (CMC) can be 
measured, if desired, using a cell line that expresses the 
target antigen. The cell line is labeled With a cytosolic 
marker, such as 51Cr. The assay is conducted by adding and 
incubating a sample suspected of containing antibody. 
Complement is added in a suitable form, such as guinea pig 
serum pre-adsorbed With the cell line. After a suitable 
incubation period at 37° C., extent of 51Cr release is then 
measured and compared With that of unopsoniZed control 
cells. 51Cr labeled target cells can also be used to measure 
antibody-dependent cell-mediated cytotoxicity (ADCC) in 
the sample, by supplying human peripheral blood mono 
nuclear cells (PBMC) from normal subjects as effector cells 
at a ratio of effectorztarget cells of about 100:1. 
A cell mediated immune response in a subject can be 
measured by isolating PBMC from a blood sample of the 
treated subject, collected into hepariniZed tubes, and sepa 
rated on a suitable gradient such as Ficoll-HypaqueTM. To 
measure T cell proliferation (a general indicator of T cell 
activation against the antigen), the cells are incubated With 
a range of concentrations of the target antigen. A non 
speci?c mitogen such as PHA serves as a positive control; 
incubation With an unrelated antigen serves as a negative 
control. After incubation of the PBMCs for an appropriate 
period (typically 5 days), [3H]thymidine incorporation is 
measured, and the proliferating cells can be further charac 
teriZed by How cytometry using cell type speci?c markers. 
Cytotoxic T cell response can be measured after a period of 
stimulation by presenting With 51Cr labeled antigen-bearing 
target cells. 
Clinical outcome is folloWed over the course of therapy 
for a therapeutic effect and undesirable side-effects, as 
illustrated in Example 4. Ideally, the compositions promote 
resolution of the clinical features, but stabiliZation of the 
condition is a satisfactory outcome. Progression or regres 
sion of the disease is folloWed according to the particular 
clinical manifestations of the original presentation, and 
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typically includes the number and size of psoriatic lesions, 
and the extent of total body surface area that is involved. 
Status can also be measured at the microscopic level as the 
proportion of epidermal cell proliferation or the proportion 
of cells expressing target antigen. 
The selection of the target antigen (or antigenic 
determinant) and the formulation of the immunogenic com 
position can be adjusted by the manufacturer, and the exact 
dose and timing for the administration can be adjusted by the 
administering physician, Without departing from the spirit of 
the invention. 
The invention also provides methods for preparing a 
composition for use in the treatment of psoriasis, comprising 
raising an anti-idiotype antibody against a monoclonal anti 
body that binds an antigenic determinant that is aberrantly 
expressed in psoriatic tissue, Wherein the anti-idiotype anti 
body is capable of eliciting an immunological response in a 
human against the antigenic determinant. Alternatively, the 
methods comprise preparing an immunogenic composition 
comprising the aberrantly expressed determinant. 
Screening Methods of the Invention 
The invention also provides methods of screening immu 
nogenic compositions for use in treatment of psoriasis in 
humans. 
In some embodiments, the methods comprise the steps of 
(a) administering to a plurality of human subjects having 
psoriasis an immungenic composition comprising an immu 
nogenic form of i) an antigenic determinant that is aberrantly 
expressed in psoriatic tissue; ii) an monoclonal anti-idiotype 
antibody for an antigenic determinant that is overexpressed 
in psoriatic tissue; or iii) an expression vector encoding 
either i) or ii); and (b) correlating the progression of the 
psoriasis in the human subjects treated in step (a) in relation 
to that ihn untreated human subjects having psoriasis, With 
the effectiveness of the immunogenic composition. 
In other embodiments, the screening methods comprise 
the folloWing steps: a) administering to a plurality of human 
subjects having psoriasis an immunogenic composition, 
comprising an immunogenic form of: i) an antigenic deter 
minant that is aberrantly expressed in psoriatic tissue; ii) a 
monoclonal anti-idiotype antibody for an antigenic determi 
nant that is aberrantly expressed in psoriatic tissue; or iii) an 
expression vector encoding either i) or ii); and b) determin 
ing the extent of an immunological response against the 
antigenic determinant in each subject treated in step a); and 
c) correlating the progression of the psoriasis in relation to 
the extent of the immunological response against the anti 
genic determinant in each subject With the effectiveness of 
the immunogenic composition. 
In any of these screening embodiments, the antigen that is 
aberrantly expressed in psoriatic tissue may preferably be a 
ganglioside, more preferably GD2. 
Kits of the Invention 
The invention also provides kits comprising a) a compo 
sition packaged in a container and comprising an immuno 
genic form of a component selected from the group con 
sisting of: i) a ganglioside; ii) an anti-idiotype for a 
ganglioside; and iii) an expression vector encoding an 
anti-idiotype for a ganglioside; and b) Written instructions 
for using the composition in the treatment of psoriasis. 
Preferably, the component is 1A7. 
The examples presented beloW are provided as a further 
guide to a practitioner of ordinary skill in the art, and are not 
meant to be limiting in any Way. 
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EXAMPLES 
Example 1 
Demonstration of Ganglioside Antigen in Psoriasis Tissue 
In this experiment, histology sections from psoriasis 
lesions Were screened for the presence of aberrantly 
expressed antigens that Would be suitable targets for an 
active vaccination strategy. 
Skin-punch biopsies Were obtained from patients having 
benign Psoriasiform Dermatitis. Paraf?n blocks from three 
samples Were cut into 5 pm cross-sections through the 
dermal layers. The sections Were ?xed onto slides and 
deparaf?niZed by a series of graduated Washes of decreasing 
ethanol content. Once equilibrated into phosphate-buffered 
saline, pH 7.4, the sections Were blocked against non 
speci?c binding by overlaying With 10% normal rabbit 
serum that had been heat-inactivated. 
After Washing, the sections Were overlaid With one of a 
panel of primary antibodies puri?ed by anion exchange 
chromatography as required, and diluted to 50 pg/mL. The 
section Was incubated With the primary antibody at room 
temperature for about an hour, and then reWashed. The 
section Was next overlaid With biotinylated rabbit anti 
mouse immunoglobulin as secondary antibody, incubated, 
and Washed. The sections Were developed using a 
streptavidin-peroxidase conjugate, folloWed by substrate. 
The panel of primary antibodies consisted of the folloW 
ing: 
Monoclonal antibody 14G2a, groWn from a hybridoma 
cell line obtained from the Scripps Research Institution. 
14G2a has been subtyped as an IgGZaK. 14G2a is 
speci?c for the ganglioside antigen GD2, and does not 
bind to gangliosides GM1, GM2, GM3, GD3, or GT1b. 
The ability of 14G2a to bind GD2 in ?xed tissue Was 
con?rmed by immunoperoxidase staining of paraf?n 
blocks of human melanoma tissue. 14G2a also speci? 
cally binds the GD2 positive melanoma cell line M21/ 
P6 When used as the primary antibody in FACS analy 
sis. 
Monoclonal antibody 8019, produced from the hybridoma 
obtained from the American Type Culture Collection 
(ATCC, Rockville Md.). 8019 has been subtyped as an 
IgG1K, and is speci?c for carcinoembryonic antigen 
(CEA). The ability of 8019 to bind CEA in ?xed tissue 
Was con?rmed by immunoperoxidase staining of par 
affin blocks of human colon cancer samples. 8019 also 
speci?cally binds the CEA positive colon cancer cell 
line LS174-T When used as the primary antibody in 
FACS analysis. 
Monoclonal antibody MC-10, also designated BrE-1, is 
speci?c for human milk fat globule (HMFG), an anti 
gen aberrantly expressed in breast cell carcinomas. 
MC-10 has been subtyped as an IgGZbK. The ability of 
MC-10 to bind HMFG in ?xed tissue sections Was 
con?rmed by immunoperoxidase staining of paraf?n 
blocks of human breast cancer samples. MC-10 also 
speci?cally binds the HMFG positive breast cancer cell 
lines MCF-7 and SKBR3 When used as the primary 
antibody in FACS analysis. 
A monoclonal mouse IgG2b of unknoWn speci?city, pur 
chased from Sigma Chemical Co., serving as a negative 
control. 
Staining intensity Was graded on a scale of (—) to (++++). 
The folloWing results Were obtained: 
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Immunohistochemical staining for aberrantlv expressed antigen 
Staining Intensitv 
Primary Antibody Sample 1 Sample 2 Sample 3 
14G2a +++ +++ +++ 
8019 ++++ ++++ ++++ 
MC10 1 1 1 
mouse IgG2b control — — — 
PBS — — — 
Both 14G2a and 8019 antibodies gave strong staining in 
all samples tested. The staining pattern was consistent with 
speci?c staining for affected tissue, since only dermal layers 
were stained. Monoclonal antibody MC10 was essentially 
negative. 
These results indicate that both GD2 and CEA are can 
didate targets for a vaccine strategy against psoriasis. 
Example 2 
Eliciting an Anti-GD2 Response in Humans using 
an Anti-idiotype 
Hybridoma cells expressing monoclonal anti-idiot anti 
body 1A7 (U.S. Pat. No. 5,612,030) were used for the 
production of ascites ?uid. 9.7 g of puri?ed antibody was 
prepared by TSD BioServices under GMP-conditions. The 
regulatory testings on the antibody preparation were com 
pleted according to FDA guidelines. This example describes 
how the antibody is tested in a human clinical study to verify 
safety and demonstrate its ability to elicit an anti-GD2 
response in humans. 
Patients are immunized with 1A7 antibody mixed with 
100 pg of QS-21 adjuvant. Patients are randomized to one of 
the four dose levels. The total number of patients is between 
about 12 and 32. Injections are given biweekly for four total 
doses, or until an immune response is observed. Therapy 
continues with monthly injections until tumor progression is 
found. Patients are monitored carefully for anaphylaxis, 
serum sickness, and other potential side effects. 
Periodic blood samples are obtained to determine the 
effect on hematopoietic cells as well as renal and hepatic 
function. All patients entered into the study undergo leuka 
pheresis prior to the ?rst immunization (pre-therapy). In 
addition, blood samples are obtained prior to each injection 
of 1A7 to determine serum levels of Ab3 and Ab1‘ antibod 
ies and cytotoxic T cell responses. The speci?city of the 
humoral responses is con?rmed by immune ?ow cytometry, 
radioimmunoassay, and dot blot analysis. Antiglobulin 
responses to the murine antibody is tested by sandwich 
radioimmunoassay. Sera are also tested for an ability to 
inhibit the binding of anti-GD2 mAb to GD2 antigen. The 
immune pro?le of patients is further assessed by testing the 
proliferative response of patient’s lymphocytes to anti 
idiotype antibody, puri?ed GD2 antigen, and irradiated 
tumor cells and the cytotoxicity of patient’s lymphocytes for 
GD2-positive HLA-matched cell lines or autologous tumor 
cells (where possible). 
What follows are the results from seven participating in 
the study over a suf?cient period to evaluate the presence of 
an immunological response. Each patient was immunized 
with 1 mg, 2 mg, 4 mg, or 8 mg of antibody 1A7 in QS-21 
on a biweekly schedule. For the ?rst few patients in the 
study, the ?rst 2 to 4 doses were given intramuscularly, and 
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periodic serum samples were collected to determine the 
presence of human anti-mouse (HAMA) activity and anti 
1A7 activity. Titers were low, and it was decided to continue 
the course of immunization subcutaneously. All patients 
seroconverted positive with respect to both HAMA and 
anti-1A7, as determined by immunoassay. The response 
comprised speci?c Ab3 activity, as demonstrated by the 
ability of each serum to inhibit the binding of radiolabeled 
1A7 to solid-phase linked 14G2a (Ab1). None of the patients 
have yet shown objective clinical responses related to their 
cancer. However, three of the seven patients (270+ to 510+ 
days) have stable disease and continue on vaccine therapy. 
The results demonstrate that administration of 1A7 as a 
pharmaceutical composition with the adjuvant QS-21 is very 
well tolerated up to a dose of 8 mg, and is highly effective 
in generating an anti-GD2 response. 
To investigate the nature of the response further, anti-1A7 
antibody was affinity puri?ed from the sera of four of the 
patents. First, each sample was passed over a column of 
14G2a antibody, eluted with a glycine buffer (pH~2.5), and 
exchanged into PBS. Next, HAMA activity that was not Ab3 
was depleted by negative selection on a mouse immunoglo 
bulin adsorbant. The amount of speci?c anti-1A7 (Ab3) 
obtained was as follows: Patient 1 (administered 1 mg 1A7 
per dose), yield 0.67 mg Ab3 from 10 mL serum. Patient 2 
(administered 2 mg 1A7 per dose), yield 1.32 mg Ab3 from 
10 mL serum. Patient 3 (administered 4 mg 1A7 per dose), 
yield 1.71 mg Ab3 from 10 mL serum. Patient 4 
(administered 4 mg 1A7 per dose), yield 0.73 mg Ab3 from 
10 mL serum. This indicates that a substantial amount of 
Ab3 is produced as a result of administering 1A7 at any of 
the doses tested, and apparently is in molar excess of antigen 
in the circulation. 
The af?nity and speci?city of the response to GD2 was 
further con?rmed by using the af?nity puri?ed Ab3 in 
several of the assay systems described earlier. In one test, an 
assay plate was coated with ganglioside GD2 or GD3, 
overlaid with puri?ed Ab3, and then developed with alkaline 
phosphatase labeled anti-immunoglobulin. The results 
showed that each patient’s response comprises the produc 
tion of anti-GD2 antibody (Ab1‘)., but not anti-GD3 anti 
body. In another test, an assay plate was coated with GD2, 
overlaid with puri?ed Ab3, and then developed with isotype 
speci?c anti-immunoglobulin reagents. The anti-GD2 
response was apparently a mature response comprising both 
IgG and IgM, with IgG predominating. 
Inhibition titration experiments were conducted using 
puri?ed Ab3 from three different patients. In one test, an 
assay plate was coated with ganglioside GD2, and varying 
amounts of puri?ed Ab3 were tested for the ability to inhibit 
the binding of radiolabeled 14G2a (Ab1). The half-titration 
point for each Ab3 was comparable to that of unlabeled 
14G2a. In another test, varying amounts of puri?ed Ab3 
were tested for their ability to inhibit the binding of radio 
labeled 14G2a to the GD2-expressing murine lymphoma 
cell line EL4. The results indicated that the Ab3 induced by 
administration of 1A7 competes for binding to GD2 aber 
rantly expressed by model target cells. 
Example 3 
Demonstration of Antibody to Psoriasis-associated Antigen 
in the Serum of Immunized Human Subjects 
Ab3 af?nity puri?ed-from the sera of human patients 
treated with an anti-idiotype were tested for the presence of 
circulating antibody against a psoriasis associated antigen. 
Patients were treated with monoclonal anti-idiotype 1A7 
(an anti-idiotype for GD2), or with anti-idiotype 3H1 (an 
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anti-idiotype for CEA). Treatment of subjects With 1A7 is 
described in Example 2. The preparation and use of 3H1 is 
described in PCT patent applications WO 96/20219 and WO 
96/20277. 
After a course of multiple immunizations on a biweekly 
immunization schedule, the respective Ab3 present in Were 
prepared by passing immune sera over an af?nity column 
made of the immunizing antibody, and recovering the bound 
fraction. As a negative control, normal or preimmune human 
IgG Was prepared by passing serum of an unimmunized 
subject over a Protein G column. 
The puri?ed IgG fractions Were then tested for their 
ability to speci?cally stain affected psoriasis tissue, using the 
immunohistochemical methods described in Example 1. The 
results are shoWn in the folloWing Table: 
TABLE 2 
Tissue staining by antibody present in the sera of immunized patients 
Staining Intensity 
Sample Sample Sample Sample 
Primary Antibody 1 2 3 4 
(Abl for 1A7; positive control) 
Ab3 from patients treated With 1A7 ++++ ++++ ++++ ++++ 
normal human IgG — — — — 
Ab3 from patients treated With 3H1 — — — — 
+++ +++ +++ +++ 
The results shoW that treatment of human patients With 
monoclonal antibody 1A7 successfully elicits an active 
immune response that is speci?c for a target antigen on 
affected psoriasis tissue. The target antigen is shared 
betWeen different psoriasis patients, and (in vieW of the 
knoWn immunogenic properties of the 1A7 antibody) most 
probably is GD2. Speci?city is con?rmed by tWo additional 
observations: a) the staining pattern With Ab3 from the 1A7 
treated subject shoWed staining of the affected skin cells but 
not surrounding muscle ?bers; b) anti-idiotype antibody 
3H1 raises a speci?c Ab3 response, but the response Was 
apparently not speci?c for psoriasis tissue. 
Example 4 
Treating Psoriasis by Eliciting an Active Anti-ganglioside 
Immunological Response 
Psoriasis afflicts approximately 1 to 2 percent of the adult 
population in various forms. Patients With extensive plaque 
psoriasis and pustular psoriasis frequently require systemic 
therapy. Topical steroids, topical calcipotriol, or ultraviolet 
light may not give adequate control. The currently used 
systemic medications such as methotrexate, etretinate and 
cyclosporine are sometimes effective, but associated With 
signi?cant side effects. 
A patient With advanced psoriasis Was administered 
monoclonal antibody 1A7 as part of a clinical trial for the 
treatment of melanoma. After leaving the trial, the patient 
returned to the attending physician (Dr. K. Foon) and 
reported that his psoriatic systems, Which had previously 
been persistent, had improved. His case history and results 
of the immunological tests Were revieWed, and it Was 
discovered that the resolution of the symptoms correlated 
With the stimulation of an anti-GD2 immune response (as 
detected in serum) during his treatment With 1A7 in the 
melanoma trial. Subsequently, psoriasis tissue samples from 
several patients Were evaluated by immunohistochemistry 
(Example 1), and all Were positive for an antigen recognized 
by anti-GD2 antibody. Antibody present in the serum of 
several patients immunized With the GD2 anti-idiotype 1A7 
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Was isolated, and found to react With a target antigen on 
psoriatic tissue (Example 3). 
This example provides a method for testing the ef?cacy of 
raising an anti-GD2 immunological response in the treat 
ment of psoriasis. 
Fifteen patients Who have been diagnosed With severe 
chronic plaque psoriasis, and Who have had an unsatisfac 
tory response to a prior systemic therapy, topical steroids or 
ultraviolet light are treated. Eligibility criteria also include 
absence of active infection or blood-born disease, adequate 
renal and hepatic function tests, granulocyte count; 1000 
mm_3> platelets>100,000 mm_3, absence of allergy to mouse 
protein, and ability to provide informed consent. Subjects 
are pre-screened for the presence of GD2 antigen on kera 
tinocytes in psoriatic lesions by immunohistology, as exem 
pli?ed in Example 1. 
FIG. 1 shoWs the scheme of treatment. The admitted 
patients are treated With 2 mg of 1A7, mixed With 100 pg of 
the adjuvant QS-21. Four injections are given initially, one 
every other Week, and then injections are given monthly. 
Treatment is stopped if there is a signi?cant adverse event, 
if there is substantial advancement of the disease, or if there 
is no signi?cant effect after six months. Patients Who shoW 
advancement of the disease are folloWed for an additional 
six months after the cessation of treatment. Patients With 
stable or improved disease six months after initiation of 
treatment receive further treatment for an additional six 
months, folloWed by another evaluation. 
During the course of the trial, patients are monitored for 
toxicity. Periodic blood samples are taken to determine any 
effect on hematopoietic cells, renal and hepatic function, 
LDH, and uric acid. The most likely side effects are local 
skin reaction, fever, chilling, and sWeating, seldom requiring 
therapy and persisting for only a feW hours. Anti-pruritics 
are used Where needed. Allergic reactions are treated symp 
tomatically With diphenhydramine or hydroxyzine. Bron 
chospasm and anaphylaxis, if they occur, are treated With 
epinephrine and supportive care, and result in removal of the 
patient from the treatment regimen. In vieW of previous tests 
of 1A7 in cancer patients (Example 2), major toxicity is not 
anticipated. 
Periodic blood samples are also taken to folloW the 
immunological response in each patient. The presence of 
antibodies against 1A7 (the Ab3 response) and against GD2 
(the Ab1‘ response) is measured by standard plate-binding 
immunoassay. Serum or isolated Ab3 is also tested for 
binding to GD2 expressed on tumor cell lines or psoriatic 
tissue. Antibody-dependent cellular cytotoxicity, T cell pro 
liferative activity, or cytotoxic T cell activity may also be 
measured according to the procedures described elseWhere 
in this disclosure. Induction of both humoral and cellular 
anti-GD2 activity is anticipated in the majority of treated 
subjects after four or more injections With the 1A7 vaccine. 
Results are determined as folloWs. Symptoms are graded 
according to the Psoriasis Area and Severity Index. Severity 
is graded on a numerical scale (0=none; 1=slight; 
2=moderate; 3=severe), taking into account erythema, 
scaling, and induration. The extent is based on total body 
surface involvement (trunk=35%; legs=35%; arms=20%; 
head and neck=10%). Progression is then graded betWeen —1 
and +3 (—1=Worse; 0=stable; +1=minimal improvement; 
+2=de?nite improvement; +3=clearing). Clinical experience 
is that Without treatment, the disease Will typically progress, 
involving more surface or having plaques With more 
erythema and induration. The treatment is considered to be 
successful if there is substantial improvement or stabiliza 
tion of the disease, compared to the typical course in patients 
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not treated With the vaccine, and initially presenting With 
similar symptoms and clinical experience. 
Although the foregoing invention has been described in 
some detail by Way of illustration and example for purposes 
of clarity and understanding, it Will be apparent to those 
skilled in the art that certain changes and mod?cations Will 
be practiced. Therefore, the description and examples should 
not be construed as limiting the scope of the invention, 
Which is delineated by the appended claims. 
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